5.56
-0.11 (-1.90%)
| Penutupan Terdahulu | 5.67 |
| Buka | 5.75 |
| Jumlah Dagangan | 2,210,378 |
| Purata Dagangan (3B) | 7,913,162 |
| Modal Pasaran | 2,047,853,696 |
| Harga / Jualan (P/S) | 402.90 |
| Harga / Buku (P/B) | 9.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Aug 2026 |
| Margin Operasi (TTM) | -1,239.23% |
| EPS Cair (TTM) | -0.910 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -54.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.02% |
| Nisbah Semasa (MRQ) | 4.07 |
| Aliran Tunai Operasi (OCF TTM) | -77.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.04 M |
| Pulangan Atas Aset (ROA TTM) | -26.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AtaiBeckley Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.67 |
|
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.78% |
| % Dimiliki oleh Institusi | 31.48% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Apr 2026 | CNBC | How Trump's psychedelics executive order could unlock stalled cannabis reform |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |